Amantadine
- Generic Name
- Amantadine
- Brand Names
- Gocovri, Osmolex
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N
- CAS Number
- 768-94-5
- Unique Ingredient Identifier
- BF4C9Z1J53
- Background
An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
- Indication
For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
- Associated Conditions
- Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism
Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Loewenstein Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02321761
- Locations
- 🇮🇱
Loewenstein Rehabilitation Center, Ra'anana, Israel
Acetylamantadine Excretion by Cancer Patients
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 120
- Registration Number
- NCT02277938
- Locations
- 🇨🇦
St. Boniface Hospital, Winnipeg, Manitoba, Canada
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
- Conditions
- DyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)
- Interventions
- Other: Placebo
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT02274766
Open-Label Safety Study of ADS-5102 in PD Patients With LID
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's Disease (PD)Dyskinesia
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT02202551
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02153632
- Locations
- 🇪🇸
Hospital General de Cataluna, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
- Conditions
- Parkinson's DiseaseLevodopa Induced Dyskinesias (LID)
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT02153645
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's DiseaseDyskinesia
- Interventions
- Other: Placebo
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02136914
Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Edward Hines Jr. VA Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02025439
- Locations
- 🇺🇸
Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
- Conditions
- Idiopathic Parkinson's DiseaseDrug Induced Dyskinesia
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT01789047
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 3
- Registration Number
- NCT01652534
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.